H

Huaxia Eye Hospital Group Co Ltd
SZSE:301267

Watchlist Manager
Huaxia Eye Hospital Group Co Ltd
SZSE:301267
Watchlist
Price: 18.19 CNY Market Closed
Market Cap: ¥15.3B

EV/GP

6.9
Current
10%
Cheaper
vs 3-y average of 7.7

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
6.9
=
Enterprise Value
¥11.4B
/
Gross Profit
¥1.8B

Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.

EV/GP
6.9
=
Enterprise Value
¥11.4B
/
Gross Profit
¥1.8B

Valuation Scenarios

Huaxia Eye Hospital Group Co Ltd is trading below its 3-year average

If EV/GP returns to its 3-Year Average (7.7), the stock would be worth ¥20.32 (12% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+96%
Average Upside
36%
Scenario EV/GP Value Implied Price Upside/Downside
Current Multiple 6.9 ¥18.19
0%
3-Year Average 7.7 ¥20.32
+12%
5-Year Average 8 ¥20.98
+15%
Industry Average 8.4 ¥22.06
+21%
Country Average 13.6 ¥35.67
+96%

Forward EV/GP
Today’s price vs future gross profit

Not enough data available to calculate forward EV/GP

Peer Comparison

All Multiples
EV/GP
P/E
All Countries
Close

Market Distribution

Lower than 74% of companies in China
Percentile
26th
Based on 6 967 companies
26th percentile
6.9
Low
0 — 8
Typical Range
8 — 23.3
High
23.3 —
Distribution Statistics
China
Min 0
30th Percentile 8
Median 13.6
70th Percentile 23.3
Max 17 898 541.1

Huaxia Eye Hospital Group Co Ltd
Glance View

Market Cap
15.3B CNY
Industry
Health Care

Huaxia Eye Hospital Group Co Ltd has positioned itself as a key player in China’s healthcare landscape, specializing in comprehensive ophthalmic services. Emerging from the early stirrings of China's reforms in the healthcare sector, Huaxia capitalized on a burgeoning demand for specialized medical care. With roots tracing back to when accessible eye care was a luxury in China, Huaxia recognized the immense potential in providing quality eye treatments. As the country urbanized rapidly, vision ailments became increasingly prevalent, creating a vast market for ocular health services. Huaxia seized this opportunity by establishing a network of state-of-the-art facilities across major cities, providing services ranging from basic eye examinations to complex surgeries. The company's revenue model is built on a multifaceted approach, combining patient volume with specialized treatments. Catering to a diverse demographic, Huaxia offers tiered service options that suit various financial capacities, ensuring a steady stream of income. Beyond individual consultations, the company has fostered partnerships with corporations and insurance providers, further securing a stable client base. Moreover, Huaxia invests significantly in pioneering medical technology and staff training, enhancing its reputation and thereby drawing more patients seeking top-notch care. Through strategic expansion and consistently leveraging advancements in ophthalmology, Huaxia Eye Hospital Group Co Ltd has solidified its place not just as a healthcare provider, but as a critical architect shaping the future of eye care in China.

Intrinsic Value
18.94 CNY
Undervaluation 4%
Intrinsic Value
Price ¥18.19
H
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett